NCT04838847View on ClinicalTrials.gov

A Study to Evaluate the Immunogenicity and Safety of the SARS-CoV-2 mRNA Vaccine CVnCoV in Elderly Adults Compared to Younger Adults for COVID-19

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 1, 2021

Primary Completion Date

January 31, 2022

Study Completion Date

September 30, 2022

Conditions
CoronavirusCovid19SARS-CoV-2Severe Acute Respiratory Syndrome
Interventions
BIOLOGICAL

CVnCoV Vaccine

Intramuscular (IM) injection

Sponsors

Lead Sponsor

CureVac
All Listed Sponsors
lead

CureVac

INDUSTRY

NCT04838847 - A Study to Evaluate the Immunogenicity and Safety of the SARS-CoV-2 mRNA Vaccine CVnCoV in Elderly Adults Compared to Younger Adults for COVID-19 | Biotech Hunter | Biotech Hunter